News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts

Analysts have upgraded Aclaris Therapeutics' revenue forecasts, leading to a 21% rise in share price. Despite expecting a decline in sales in 2025, analysts are more optimistic, reducing loss estimates.